Received Feb 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 4 | U7969AA | IM / LL |
| FLUN4 | INFLUENZA (SEASONAL) (FLUMIST QUADRIVALENT) | MEDIMMUNE VACCINES, INC. | 1 | WF2584 | IN / NS |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | T5727 | IM / RL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y013583 | SC / LL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 4 | HR3906 | IM / RL |
On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client was refrigerated on 10/1/24 until admin on 11/20/24.